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Introduction
Portal hypertension and portal-systemic shunting are
clinical features in patients with liver cirrhosis. The
development of a portal-systemic collateral circulation
may lead to lethal complications, such as hepatic
encephalopathy, gastroesophageal varices, and variceal
bleeding. The pathogenesis of collateralization is
unknown, but may be related to the presence of portal
hypertension and hyperdynamic circulation.1
Nitric oxide (NO) is a potent vascular endothelium-
derived vasodilator produced from L-arginine. It can
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be synthesized by various key enzymes, with 2 distinct
isoforms: constitutive NO synthase (cNOS) and
inducible NO synthase (iNOS).2 In many cell types,
cNOS synthesizes NO to maintain basal vascular tone
and physiologic homeostasis, whereas iNOS is
transiently induced by serum, growth factors, cytokines,
tumor necrosis factor, endotoxins, and other factors.3
Chronic administration of Nt-nitro-L-arginine (NNA),
a non-selective NOS inhibitor, ameliorates portal-
systemic shunting in portal hypertensive rats, which
suggests that NO plays a role in collateralization of the
portal system.1 Recently, an in situ perfusion model of
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the collateral circulation was developed successfully in
rats with partial portal vein ligation (PVL).4 Using this
model, some authors demonstrated that NO is involved
in modulating the vascular response to vasoconstrictors
in the portal-systemic collaterals of rats with PVL.5,6
However, the contribution of NOS isoforms in the
collateral circulation remains unknown.
In the present study, NNA and aminoguanidine
(AG; a preferential iNOS inhibitor)7,8 were used to
clarify which isoform of NOS is involved in the collateral
circulation of portal hypertensive rats.
Methods
Study animals
Adult male Sprague-Dawley rats, weighing 300–350 g
at the time of surgery, were used for study. The rats
were housed in a plastic cage in a 12-hour light-dark
cycle, and were allowed free access to food and water
until the time of the experiments. All rats were fasted
for 12 hours before operation. In all experiments, the
investigators adhered to American Physiological Society
Guiding Principles for the Care and Use of Laboratory
Animals. Survival surgery was performed under ether
anesthesia, followed by intramuscular ketamine
hydrochloride (100 mg/kg bodyweight). Portal
hypertension was induced by partial PVL, as
previously reported.9 In brief, the portal vein was
isolated and a 3-0 silk ligature was tied around the
portal vein and an adjacent 20-gauge blunt-tipped
needle. The needle was then removed, allowing the
vein to re-expand. A second loose ligature was left
around the portal vein, with two endings of the
ligature placed on each side in the abdominal cavity.
The abdomen was then closed and the animal was
allowed to recover. Perfusion studies were performed
in overnight-fasted rats 10–13 days after the operation,
when extensive collateralization of the portal system
was fully established.10 Bodyweight and mean arterial
pressure of the rats were measured on the day of
perfusion studies.
In situ perfusion of portal-systemic collaterals
In situ perfusion studies were performed as previously
described.4,5 Both jugular veins were cannulated with
16-gauge Teflon cannulas to ensure an adequate
outflow, without resistance even at the highest flow
rates. Heparin (200 U/100 g bodyweight) was injected
through one of the cannulas. The abdomen was then
opened and an 18-gauge Teflon cannula inserted in
the distal mesenteric vein and fixed with cyanoacrylate
glue. To prevent liver perfusion, a second loose ligature
was tied around the portal vein. The animal was
transferred into a warm chamber (37 ( 0.5$C). The
temperature around the perfusion area was
continuously monitored, with a thermometer placed
inside the mesentery, and was maintained at
approximately 37 ( 0.5$C with a thermostatic pad and
temperature-controlled infrared lamp. Open-circuit
perfusion was then started with Krebs solution
(composition in mmol/L: NaCl 118; KCl 4.7; KH2PO4
1.2; MgSO4 1.2; CaCl2 2.5; NaHCO3 25.0; dextrose
11.0; pH 7.4; 37 ( 0.5$C) via the mesenteric cannula
by a roller pump (model 505S, Wastson-Marlow Ltd,
Falmouth, Cornwall, England). The perfusate was
equilibrated with carbogen gas (95% O2, 5% CO2) by
a silastic membrane lung.11 Both jugular vein cannulas
were simultaneously opened to allow a complete
washout of the blood. Pneumothorax was created by
opening slits through the diaphragm to increase
resistance in the pulmonary artery and prevent perfusate
from entering the left heart chambers.
The portal-systemic collaterals were then perfused
with oxygenated (95% O2, 5% CO2) Krebs solution
containing 3% w/v albumin (factor V bovine serum
albumin; Sigma Chemical Co, St. Louis, MO, USA).
The effluent of the perfused tissue was collected in a
reservoir and was not recirculated. To monitor and
continuously record pressure in the portal-systemic
collaterals, a Spectramed DTX transducer attached to
the Gould model RS 3400 recorder (Gould Inc,
Cupertino, CA, USA) was connected to a side arm
placed just proximal to the perfusion cannula, with the
0 placed at the level of the right atrium. As temperature
and pressure of the system stabilized within 20 minutes,
all experiments were performed 30 minutes after starting
perfusion at a constant rate of 20 mL/min. Since the
perfusion flow rate was kept constant throughout the
experiment, changes in perfusion pressure reflected
changes in collateral vascular resistance.
Experimental design
The relaxation response of acetylcholine (ACh) in
norepinephrine (NE)-preconstricted portal-systemic
collaterals in the presence or absence of AG or NNA
was investigated. Three groups of rats were used:
vehicle (Krebs solution) plus NE and ACh (n = 7); AG
(10–4 M) plus NE and ACh (n = 6); and NNA (10–4 M)
plus NE and ACh (n = 7). In the experiment, portal-
systemic collaterals were preconstricted with 0.3 +M
NE, a concentration causing a half maximal effect,4 to
evaluate the relaxation response to ACh. To retard the
oxidation of NE, ascorbate 0.2 +M was used. ACh
(10–8 M, 10–7 M and 10–6 M) was introduced into the
perfusate 5 minutes after challenge with NE, and each
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concentration was allowed to stabilize for 3 minutes
before the next higher concentration was added. NOS
inhibitors or vehicle were introduced into the perfusate
15 minutes before the NE challenge and were present
throughout subsequent stimulations. Only 1
concentration-response curve was performed for each
preparation.
Drugs
The reagents for preparing Krebs solution, NE, ACh,
AG, and NNA were purchased from Sigma Chemical
Co. All drugs were prepared freshly for each
experimental day.
Statistical analysis
Results are expressed as mean ( standard error. Changes
in perfusion pressure from baseline were calculated for
each concentration of each preparation. Statistical
analyses were performed using the paired or unpaired
Student’s t test, and 1-way analysis of variance with
Tukey’s test when appropriate. A p value of less than
0.05 was considered statistically significant.
Results
Table 1 shows the baseline characteristics of rats in the
different groups studied. No significant, between-
group differences were observed in bodyweight,
number of days of PVL, and mean arterial pressure.
Preincubation with NNA, but not AG, significantly
increased baseline perfusion pressure relative to the
vehicle group (NNA vs AG and vehicle: 20.3 ( 0.8
vs 12.6 ( 0.8 and 13.6 ( 1.6 mmHg, respectively; p <
0.05). In the vehicle group, NE preconstriction sig-
nificantly elevated perfusion pressure from baseline
(change from baseline perfusion pressure: 4.8 ( 0.6
mmHg; p < 0.05). The above-baseline increase in
perfusion pressure in response to NE was significantly
enhanced in the presence of NNA (7.4 ( 1.0 mmHg;
p < 0.05), but not AG (4.5 ( 0.6 mmHg) (Figure 1).
Table 2 shows ACh-induced percent changes in
perfusion pressure (from NE-induced preconstriction)
in portal-systemic collaterals. ACh induced progres-
sive, concentration-dependent relaxation of initial
NE-induced constriction in the vehicle group.
Table 1. Baseline characteristics of rats in the different study groups
Characteristic Vehicle (n = 7) AG (n = 6) NNA (n = 7)
Bodyweight (g) 351.6 ( 15.2 347.8 ( 5.7 319.4 ( 11.3
Days of PVL 11.7 ( 0.8 11.4 ( 1.2 10.1 ( 0.9
MAP (mmHg) 86.8 ( 4.4 82.3 ( 7.5 86.8 ( 4.3
BPP (mmHg) 13.6 ( 1.6 12.6 ( 0.8 20.3 ( 0.8*
*p < 0.05 vs AG and vehicle. AG = aminoguanidine; BPP = baseline perfusion pressure; MAP = mean arterial pressure; NNA = Nt-nitro-L-arginine;
PVL = partial portal vein ligation.
Table 2. ACh-induced percent changes in perfusion pressure (from NE-induced preconstriction) in portal-systemic collaterals
in the different study groups
Vehicle (n = 7) AG (n = 6) NNA (n = 7)
10–8 M ACh –14.3 ( 2.6 –11.6 ( 0.7 –8.0 ( 2.0
10–7 M ACh –37.4 ( 3.5 –32.4 ( 5.6 –15.0 ( 4.3*
10–6 M ACh –51.4 ( 5.4 –44.9 ( 7.2 –14.2 ( 5.7*
*p < 0.05 vs AG and vehicle. Values shown are mean ( standard error percent changes in perfusion pressure relative to NE-induced preconstriction.
ACh = acetylcholine; AG = aminoguanidine; NNA = Nt-nitro-L-arginine.
Figure 1. Change in perfusion pressure in portal-systemic
collaterals after challenge with norepinephrine, with or without
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Preincubation with NNA, but not AG, significantly
suppressed (p < 0.05) ACh-induced relaxation in the
portal-systemic collaterals.
Discussion
The in situ model of portal-systemic collateral perfusion
used in this study is a stable and highly reproducible
model that can be used to investigate the response of
portal-systemic collaterals to various pharmaceutical
agents in portal hypertensive status.4–6 In addition, for
pharmacologic study, it is a highly sensitive and
reproducible technique for evaluating the collateral
vasculature. This collateral-perfusion technique dem-
onstrated that the flow-pressure slope (i.e. vascular
resistance in the portal-systemic collateral vasculature)
decreased significantly and progressively from days
2–7 after induction of portal hypertension in the rats;4
this is compatible with observations using the
microsphere method.10 The in situ perfusion model
evaluates resistance to flow across all portal-systemic
collateral vessels, whereas the radioactive microsphere
technique cannot evaluate vessels with a diameter
greater than that of the microspheres (~15 ( 0.1 +m).
In addition, the non-recirculating perfusion system
excludes the influence of vasoactive substances released
from anoxic organs during experiments.5
According to a previous study by Mosca et al,4
concentration-dependent relaxation to ACh
concentrations of 10–8–10–6 M was exhibited in the
perfused collaterals of portal hypertensive rats.
Maximal ACh-induced vasodilation reduced NE-
induced preconstriction by about 50%. As such
vasodilation is mediated by NO, and as NO is an
endothelium-derived vasodilatory substance, the
study also tested the role of the endothelium in the
vasodilatory effect of ACh. Results showed that
removal of the portal-systemic collateral vascular
endothelium, with sodium cholate 1%, blunted the
vasodilatory effect of ACh.4 In the present study,
which surveyed the relative contribution of different
NOS subtypes,  vehic le-treated rats  had a
concentration-dependent relaxation to ACh. The
non-selective NOS inhibitor NNA significantly
diminished (p < 0.05) the vasodilatory response to
ACh, even at an ACh concentration of 10–6 M
(–14.2% with NNA, vs –51.4% and –44.9% with
vehicle and AG, respectively). However, a similar
effect was not observed with AG, a preferential iNOS
inhibitor. These results suggest that the enhanced
NO activity in the collateral vascular bed of portal
hypertensive rats is due to cNOS rather than iNOS.
In the present study, NE preconstriction sig-
nificantly increased perfusion pressure in portal-
systemic collaterals in the vehicle group. Preincuba-
tion with NNA not only increased baseline perfu-
sion pressure, but also potentiated NE-induced
vasoconstriction. This finding is consistent with the
previous report by Mosca et al.4 Preincubation with
NNA also enhanced the vasoconstrictive effects of
vasopressin and endothelin on the portal-systemic
collaterals in portal hypertensive rats, as demonstrated
in previous studies.5,6 However, the preferential iNOS
inhibitor AG, unlike NNA, had no major effects on
baseline perfusion pressure or NE-induced vaso-
constriction in the portal-systemic collaterals.
Considerable debate exists about which NOS
isoforms are responsible for the development of
hyperdynamic circulation in portal hypertension. With
measurements of cNOS and iNOS activity, Fernándes
et al12 demonstrated that iNOS is not required for
development of the hyperkinetic systems and splanch-
nic circulation in PVL or cirrhotic rats. In addition,
Soubrane et al13 observed no iNOS gene expression in
the aorta of cirrhotic or PVL rats. However, cloning
studies in experimental portal hypertension have dem-
onstrated iNOS mRNA expression in the arteries of
cirrhotic rats,14,15 and in the endothelia of esophageal
submucosal veins in PVL rats.16 Recently, cNOS, but
not iNOS, expression was found in the thymus, aorta,
heart, lung, esophagus, liver, spleen, kidney, pancreas,
and small and large intestine.17 In addition, using
cNOS or iNOS gene-knockout mice, Theodorakis et
al18 reported that cNOS, rather than iNOS, is important
in the pathogenesis of portal hypertension. Our study
also demonstrated a lack of iNOS activity in the col-
lateral circulation, and all these observations suggest
that it is primarily cNOS that contributes to increased
NO activity in the collateral vascular bed in portal
hypertension.
Regarding the effect of NO on portal-systemic
collateral formation, it has been found that NO
inhibition ameliorates portal-systemic shunting in
portal hypertensive rats.1,19 Recently, the role of NO as
an autocrine regulator of the microvascular events
necessary for angiogenesis has also been reported,20,21
which supports the notion that cautious NO inhibition
may contribute to improved control over varices
formation in patients with liver cirrhosis. The relative
contribution of NOS isoforms also requires further
delineation.
In conclusion, preincubation with a non-selective
NOS inhibitor, NNA, but not the preferential iNOS
inhibitor, AG, enhanced NE-induced vasoconstriction
and suppressed ACh-induced vasodilatation in portal-
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systemic collaterals in portal hypertensive rats. These
findings suggest that the main source of NO
production in the collateral circulation depends on
cNOS activity.
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